Bavarian Nordic (OTCMKTS:BVNRY) Share Price Passes Above 50-Day Moving Average - What's Next?

Key Points

• Bavarian Nordic's stock price surpassed its 50-day moving average of $11.76, reaching a high of $12.07 during Thursday's trading session.
• The company reported earnings of $0.23 per share for the last quarter, with revenues totaling $251.14 million.
• Bavarian Nordic specializes in developing life-saving vaccines, including those for smallpox, monkeypox, rabies, and Ebola.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report)'s share price passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $11.76 and traded as high as $12.07. Bavarian Nordic shares last traded at $12.07, with a volume of 607 shares.

Bavarian Nordic Trading Up 0.9%

The stock has a 50-day simple moving average of $11.87 and a 200 day simple moving average of $9.51. The stock has a market capitalization of $2.88 billion, a price-to-earnings ratio of 13.92 and a beta of 1.30.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) last issued its earnings results on Friday, August 22nd. The company reported $0.23 earnings per share for the quarter. The company had revenue of $251.14 million for the quarter. Bavarian Nordic had a return on equity of 12.35% and a net margin of 21.95%. Sell-side analysts expect that Bavarian Nordic will post 0.67 earnings per share for the current fiscal year.

Bavarian Nordic Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.